40 related articles for article (PubMed ID: 28506716)
1. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
Parakh S; Park JJ; Mendis S; Rai R; Xu W; Lo S; Drummond M; Rowe C; Wong A; McArthur G; Haydon A; Andrews MC; Cebon J; Guminski A; Kefford RF; Long GV; Menzies AM; Klein O; Carlino MS
Br J Cancer; 2017 Jun; 116(12):1558-1563. PubMed ID: 28524161
[TBL] [Abstract][Full Text] [Related]
2. Dabrafenib plus trametinib in patients with BRAF
Davies MA; Saiag P; Robert C; Grob JJ; Flaherty KT; Arance A; Chiarion-Sileni V; Thomas L; Lesimple T; Mortier L; Moschos SJ; Hogg D; Márquez-Rodas I; Del Vecchio M; Lebbé C; Meyer N; Zhang Y; Huang Y; Mookerjee B; Long GV
Lancet Oncol; 2017 Jul; 18(7):863-873. PubMed ID: 28592387
[TBL] [Abstract][Full Text] [Related]
3. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances.
Haroun F; Millado K; Tabbara I
Anticancer Res; 2017 Jun; 37(6):2777-2783. PubMed ID: 28551613
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Profiling in
Wongchenko MJ; McArthur GA; Dréno B; Larkin J; Ascierto PA; Sosman J; Andries L; Kockx M; Hurst SD; Caro I; Rooney I; Hegde PS; Molinero L; Yue H; Chang I; Amler L; Yan Y; Ribas A
Clin Cancer Res; 2017 Sep; 23(17):5238-5245. PubMed ID: 28536307
[No Abstract] [Full Text] [Related]
5. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
6. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.
Nti AA; Serrano LW; Sandhu HS; Uyhazi KE; Edelstein ID; Zhou EJ; Bowman S; Song D; Gangadhar TC; Schuchter LM; Mitnick S; Huang A; Nichols CW; Amaravadi RK; Kim BJ; Aleman TS
Retina; 2019 Mar; 39(3):502-513. PubMed ID: 29324592
[TBL] [Abstract][Full Text] [Related]
7. Cobimetinib: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Oct; 75(15):1823-30. PubMed ID: 26452567
[TBL] [Abstract][Full Text] [Related]
8. Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.
Eagles JR; Jimeno A
Drugs Today (Barc); 2016 Nov; 52(11):593-605. PubMed ID: 28112278
[TBL] [Abstract][Full Text] [Related]
9. [Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].
Kastl G
Ophthalmologe; 2019 Aug; 116(8):785-788. PubMed ID: 30357465
[TBL] [Abstract][Full Text] [Related]
10. En Face Widefield OCT Angiography of MEK Inhibitor-Associated Retinopathy.
Kunkler AL; Lam BL; Sridhar J
Ophthalmology; 2021 Jul; 128(7):1015. PubMed ID: 34154722
[No Abstract] [Full Text] [Related]
11. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
de la Cruz-Merino L; Di Guardo L; Grob JJ; Venosa A; Larkin J; McArthur GA; Ribas A; Ascierto PA; Evans JTR; Gomez-Escobar A; Barteselli G; Eng S; Hsu JJ; Uyei A; Dréno B
J Transl Med; 2017 Jun; 15(1):146. PubMed ID: 28646893
[TBL] [Abstract][Full Text] [Related]
12. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
[No Abstract] [Full Text] [Related]
13. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
[TBL] [Abstract][Full Text] [Related]
14. MEK Retinopathy. Clinical case reports.
Rocha Cabrera P; Quijada Fumero E; Losada Castillo MJ; Abreu Reyes JA; Lorenzo Morales J
Arch Soc Esp Oftalmol (Engl Ed); 2018 Jan; 93(1):42-46. PubMed ID: 28506716
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
